BRAF and metastatic melanoma: In this study, patients with previously treated unresectable or metastatic melanoma, both mutant and wild type BRAF, are randomized to receive Spartalizumab combined with a second agent between Ribociclib, Capmatinib, Canakinumab, and LAG525.